查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
病毒和非病毒載體製造市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按載體類型、按適應症、按應用、按公司和區域分類
市場調查報告書
商品編碼
1289659

病毒和非病毒載體製造市場 - 2017-2027年全球行業規模、佔有率、趨勢、機會和預測，按載體類型、按適應症、按應用、按公司和區域分類

Viral & Non-Viral Vector Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Vector Type, By Indication, By Application, By Company and By Region
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球病毒和非病毒載體製造市場預計將在2023-2027年的預測期間出現令人印象深刻的成長。主要因素包括致命疾病的流行率上升，基因和細胞治療產品的日益突出，以及技術的廣泛發展，這些都推動了市場的成長。載體是基因傳遞的工具，它將遺傳物質傳遞到核細胞中。它們有兩種類型，病毒載體和非病毒載體。病毒載體是FDA批准的基因療法中常用的傳遞工具，而非病毒載體的安全性和有效性仍在研究中。支持市場成長的其他因素有：廣泛的研究和開發，越來越多的病人，越來越多的臨床研究，私人以及公共部門的各種投資，基於載體的基因和細胞治療越來越普遍，公司之間的合作越來越多，以及對定製藥物的高需求。

致命疾病的發病率不斷上升

遺傳性疾病、癌症和傳染病，如糖尿病、唐氏綜合症、流感、肝癌、阿滋海默症、心血管疾病和其他疾病，在全球範圍內的發生率越來越高，這促進了市場的成長。根據世衛組織的數據，心血管疾病（CVDs）是全球死亡的主要原因，每年奪去約1790萬人的生命。按照世衛組織的說法，癌症是一個主要的死亡原因，報告了近1000萬例死亡，或在2020年近六分之一的死亡。由於患有這些致命疾病的病人越來越多，對用於治療的載體的需求正在上升。例如，在2019年，美國食品和藥物管理局批准了MVA（改良的安卡拉疫苗病毒），市場名稱為Jynneos，用於預防天花和猴痘。

基因和細胞治療產品的地位日益突出

基因療法是一種借助於遺傳物質來治療或預防疾病的方法。先進的基因和細胞療法，通過使用載體，對生物醫學領域產生了很大的影響。經過各種研究，人們發現，載體不僅用於預防或治療特定的疾病，而且利用它們所具有的遺傳資訊，可以直接針對疾病的原因，並能改變細胞的功能方式。基於載體的基因和細胞治療的普及率不斷提高，也是市場成長的一個因素。因此，眾多創新公司正積極參與開發和生產用於細胞和基因治療的病毒載體和非病毒載體。例如，在2022年，美國FDA批准了第二個CAR-T療法，名為CARVYKTI（TM），由強生公司開發，用於治療復發或難治性多發性骨髓瘤。

可用的定製方法

利用給定的市場數據，TechSci Research根據公司的具體需要提供定製服務。該報告可提供以下定製選項：

公司資訊

  • 其他市場參與者（最多5家）的詳細分析和概況。

目錄

第一章：產品概述

第二章：研究方法

第三章：執行摘要

第四章：COVID-19對全球病毒和非病毒載體製造市場的影響

第五章：客戶的聲音

第六章：全球病毒和非病毒載體製造市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按載體類型（病毒性載體和非病毒性載體）分類
    • 按適應症（癌症、遺傳病、傳染病、心血管疾病、其他）分類
    • 按應用（基因治療、疫苗學、細胞治療、其他）分類
    • 按地區分類
    • 按公司分類(2021年)
  • 市場地圖

第七章：北美病毒和非病毒載體製造市場展望

  • 市場規模和預測
    • 按價值分類
  • 市場佔有率與預測
    • 按載體類型（病毒性載體和非病毒性載體）分類
    • 按適應症（癌症、遺傳病、傳染病、心血管疾病、其他）分類
    • 按應用（基因治療、疫苗學、細胞治療、其他）分類
    • 按國家分類
  • 北美洲：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第8章：歐洲病毒和非病毒載體製造市場前景

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率和預測
    • 按載體類型（病毒性載體和非病毒性載體）分類
    • 按適應症（癌症、遺傳病、傳染病、心血管疾病、其他）分類
    • 按應用（基因治療、疫苗學、細胞治療、其他）分類
    • 按國家分類
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第九章：亞太地區病毒和非病毒載體製造市場展望

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率和預測
    • 按載體類型（病毒性載體和非病毒性載體）分類
    • 按適應症（癌症、遺傳病、傳染病、心血管疾病、其他）分類
    • 按應用（基因治療、疫苗學、細胞治療、其他）分類
    • 按國家分類
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第十章：南美病毒和非病毒載體製造市場展望

  • 市場規模和預測
    • 按價值計算
  • 市場佔有率和預測
    • 按載體類型（病毒性載體和非病毒性載體）分類
    • 按適應症（癌症、遺傳病、傳染病、心血管疾病、其他）分類
    • 按應用（基因治療、疫苗學、細胞治療、其他）分類
    • 按國家分類
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章：中東和非洲病毒和非病毒載體製造市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按載體類型（病毒載體與非病毒載體）分類
    • 按適應症（癌症、遺傳病、傳染病、心血管疾病、其他）分類
    • 按應用（基因治療、疫苗學、細胞治療、其他）分類
    • 按國家分類
  • MEA: 國家分析
    • 南非病毒和非病毒載體製造
    • 沙烏地阿拉伯病毒和非病毒載體製造
    • 阿拉伯聯合大公國病毒和非病毒載體製造

第12章：市場動態

  • 驅動力
  • 挑戰

第十三章：市場趨勢與發展

第14章：競爭格局

  • Catalent, Inc.FUJIFILM Holdings Corporation Danaher Corporation Genscript Biotech Corporation Lonza Group AG Merck KGaA Inc.Oxford Biomedica plc Sartorius AG Takara Bio Inc.賽默飛世爾科技公司

第十五章：戰略建議

簡介目錄
Product Code: 13100

The global viral & non-viral vector manufacturing market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include the rising prevalence of fatal diseases, the growing prominence of gene and cell therapy products, and extensive development in technology, which are propelling the growth of the market. Vectors are tools for gene delivery, which deliver genetic material into the nucleic cell. They are of two types, viral and non-viral vectors. Viral vectors are commonly used delivery vehicles in FDA-approved gene therapies, whereas non-viral are still studied for their safety and efficacy. The other factors supporting the market's growth are the extensive research and development, an increasing number of patients, an increasing number of clinical studies, various investments by private as well public sectors, increasing prevalence of vector-based gene and cell treatments, the growing number of collaborations between companies, and the high demand for customized medications.

Rising Prevalence of Fatal Diseases

The increasing occurrence of genetic disorders, cancers, and infectious diseases, such as diabetes, down syndrome, flu, liver cancer, Alzheimer's disease, cardiovascular diseases, and others, across the globe are bolstering the growth of the market. According to the WHO, Cardiovascular diseases (CVDs) are the leading cause of death worldwide, taking approximately 17.9 million lives each year. As per WHO, cancer is a leading cause of death, reporting almost 10 million deaths, or nearly one in six deaths in 2020. Owing to the increasing number of patients suffering from these fatal diseases, the demand for vectors for treatment is rising. For instance, in 2019, the FDA approved MVA (Modified Vaccinia virus Ankara), under the market name Jynneos, to prevent both smallpox and monkeypox.

Growing Prominence of Gene and Cell Therapy Products

Gene therapy is a method to treat or prevent disease with the help of genetic material. Advanced gene and cell therapies, with the use of vectors, have considerably impacted the field of biomedicine. After various research, it is found that the vectors are not only used to prevent or treat specific diseases, but with the genetic information they have, they can directly target the cause of the disease and can alter the way a cell functions. The rising prevalence of vector-based gene and cell treatments is also a contributing factor to the growth of the market. Therefore, numerous innovator companies are actively involved in the development and production of viral vectors and non-viral vectors for cell and gene therapies. For instance, in 2022, the USFDA approved the second CAR-T therapy named CARVYKTI™, developed by Johnson and Johnson, which is used for the treatment of relapsed or refractory multiple myeloma.

Market Segmentation

The global viral & non-viral vector manufacturing market is segmented into vector type, indication, application, and company. Based on vector type, the market is segmented into viral vector and non-viral vector. Based on viral vector, the market is further segmented into adenoviral vector, retroviral vector, lentiviral vector, vaccinia viral vector, and others. Based on non-viral vector, the market is further segmented into plasmid DNA, lipid-based non-viral vector, polymer-based non-viral vector, and others. Based on indication, the market is divided into cancer, genetic disease, infectious disease, cardiovascular diseases, and others. Based on application, the market is divided into gene therapy, vaccinology, cell therapy, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising prevalence of genetic disorders, infectious diseases, chronic diseases, and cancers in the country.

Market Players

Catalent, Inc., FUJIFILM Holdings Corporation, Danaher Corporation, Genscript Biotech Corporation, Lonza Group AG, Merck KGaA Inc., Oxford Biomedica plc, Sartorius AG, Takara Bio Inc., and Thermo Fisher Scientific Inc are some of the leading companies operating in the market.

Report Scope

In this report, global viral & non-viral vector manufacturing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Viral & Non-Viral Vector Manufacturing Market, By Vector Type:

  • Viral Vector
    • Adenoviral Vector
    • Retroviral Vector
    • Lentiviral Vector
    • Vaccinia Viral Vector
    • Others
  • Non-Viral Vector
    • Plasmid DNA
    • Lipid-Based Non-Viral Vector
    • Polymer-Based Non-Viral Vector
    • Others

Viral & Non-Viral Vector Manufacturing Market, By Indication:

  • Cancer
  • Genetic Disease
  • Infectious Disease
  • Cardiovascular Diseases
  • Others

Viral & Non-Viral Vector Manufacturing Market, By Application:

  • Gene Therapy
  • Vaccinology
  • Cell Therapy
  • Others

Viral & Non-Viral Vector Manufacturing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Viral & Non-Viral Vector Manufacturing Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Viral & Non-Viral Vector Manufacturing Market

5. Voice of Customer

6. Global Viral & Non-Viral Vector Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 6.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 6.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 6.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 6.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2021)
  • 6.3. Market Map

7. North America Viral & Non-Viral Vector Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 7.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 7.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 7.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 7.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Viral & Non-Viral Vector Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vector Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Application
    • 7.3.2. Mexico Viral & Non-Viral Vector Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vector Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Application
    • 7.3.3. Canada Viral & Non-Viral Vector Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vector Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Application

8. Europe Viral & Non-Viral Vector Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 8.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 8.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 8.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 8.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vector Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Application
    • 8.3.2. Germany Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vector Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Application
    • 8.3.3. United Kingdom Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vector Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Application
    • 8.3.4. Italy Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vector Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Application
    • 8.3.5. Spain Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vector Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Application

9. Asia-Pacific Viral & Non-Viral Vector Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 9.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 9.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 9.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 9.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vector Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Application
    • 9.3.2. India Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vector Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Application
    • 9.3.3. Japan Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vector Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Application
    • 9.3.4. South Korea Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Vector Type
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By Application
    • 9.3.5. Australia Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Vector Type
        • 9.3.5.2.2. By Indication
        • 9.3.5.2.3. By Application

10. South America Viral & Non-Viral Vector Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 10.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 10.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 10.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 10.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Viral & Non-Viral Vector Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vector Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Application
    • 10.3.2. Argentina Viral & Non-Viral Vector Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vector Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Application
    • 10.3.3. Colombia Viral & Non-Viral Vector Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vector Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Application

11. Middle East and Africa Viral & Non-Viral Vector Manufacturing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 11.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 11.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 11.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 11.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Viral & Non-Viral Vector Manufacturing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Vector Type
        • 11.3.1.2.2. By Indication
        • 11.3.1.2.3. By Application
    • 11.3.2. Saudi Arabia Viral & Non-Viral Vector Manufacturing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Vector Type
        • 11.3.2.2.2. By Indication
        • 11.3.2.2.3. By Application
    • 11.3.3. UAE Viral & Non-Viral Vector Manufacturing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Vector Type
        • 11.3.3.2.2. By Indication
        • 11.3.3.2.3. By Application

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Catalent, Inc.
  • 14.2. FUJIFILM Holdings Corporation
  • 14.3. Danaher Corporation
  • 14.4. Genscript Biotech Corporation
  • 14.5. Lonza Group AG
  • 14.6. Merck KGaA Inc.
  • 14.7. Oxford Biomedica plc
  • 14.8. Sartorius AG
  • 14.9. Takara Bio Inc.
  • 14.10. Thermo Fisher Scientific Inc

15. Strategic Recommendations